Stay updated with breaking news from Nova Plc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LivaNova PLC (NASDAQ:LIVN – Get Rating) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 1,940,000 shares, a decline of 13.0% from the February 28th total of 2,230,000 shares. Based on an average daily trading volume, of 523,900 shares, the […]
Putnam Investments LLC lessened its holdings in LivaNova PLC (NASDAQ:LIVN – Get Rating) by 1.8% in the 3rd quarter, Holdings Channel reports. The firm owned 35,404 shares of the company’s stock after selling 644 shares during the quarter. Putnam Investments LLC’s holdings in LivaNova were worth $1,798,000 as of its most recent SEC filing. Other […]
/PRNewswire/ -- The "Neuromodulation Devices Global Market- Forecast To 2029" report has been added to ResearchAndMarkets.com's offering. The neuromodulation...
/PRNewswire/ -- The thoracic catheters market size is expected to increase by USD 154.02 mn from 2021 to 2026. The growth momentum of the market will...
Markets Needham analyst Michael Matson maintained a Hold rating on LivaNova (LIVN – Research Report) today. The company’s shares closed last Wednesday at $87.05. According to TipRanks.com, Matson is a 5-star analyst with an average return of 17.3% and a 72.0% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings. LivaNova has an analyst consensus of Moderate Buy, with a price target consensus of $88.00. LivaNova’s market cap is currently $4.03B and has a P/E ratio of -11.60. The ...